Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

Figures & data

Figure 1. Effects of immunomodulatory oligonucleotides and everolimus on neoplastic lesions. Mechanisms of action of immunomodulatory oligonucleotides (IMOs) and the mTOR inhibitor everolimus on different cell populations of the tumor microenvironment, including malignant, endothelial as well as immune cells.